Migraine Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: May 01, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 5.13 billion |
|
Revenue Forecast in 2031 |
US$ 11.43 billion |
|
CAGR |
9.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Migraine Type, Route Of Administration, And Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global migraine therapeutics market was valued at US$ 5.13 billion in 2022 and is expected to register a revenue CAGR of 9.3% to reach US$ 11.43 billion by 2031.
Migraine Therapeutics Market Fundamentals
According to the 2019 worldwide Burden of Disease research, migraine is the second most cause of worldwide disability and the leading cause among young women. Migraine is a neurological disorder that produces throbbing, pulsating headaches, nausea, and sensitivity to light, sound, and motion. It can last at least four hours but might extend for days for some people. Migraine has a worldwide distribution: across all continents, although its incidence varies geographically, being greater in North, South, and Central America, intermediate in Asia, and lowest in Africa. Because the pathophysiology of migraine is still unknown, there is no complete cure.
Based on headache frequency, there are two primary clinical segments of migraine: episodic migraine (EM), in which patients have 15 headache days per month, and chronic migraine (CM), in which patients have 15 headache days per month, with at least 8 of those days having migrainous symptoms. Migraine therapy is split into two paradigms: acute treatment, which is delivered as an abortive treatment at the outset of an attack, and prophylactic treatment, which is given on a long-term basis to avoid subsequent migraine episodes.
There are several pharmacological alternatives available to prevent and cure migraine episodes. Migraine pharmacotherapy focuses on both acute treatment (addressing a migraine attack after it has begun) and preventative medication (preventing or reducing the frequency or severity of migraine attacks). Non-specific pain pharmacotherapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, or migraine specific, such as triptans and ergot derivatives, and more recently, gepants (CGRP, receptor antagonists developed for the acute treatment of migraine attacks), and ditans (a newer class of acute medication for the treatment of migraine attacks that specifically targets the 5-HT1Freceptor), are used to treat acute migraine attacks.
[57567]
Migraine Therapeutics Market Dynamics
The increase in migraine incidence is a key driver of the global migrain therapeutics market growth. Improved payment rules for migraine therapy, as well as the growing demand for precision drugs, are also contributing to the market's growth. Rising demand for electrical nerve stimulating devices to treat migraines and the anticipated approval of new types of late-stage pipeline medications are driving market expansion. All these determinants keep the global migraine therapeutics industry trends positive throughout the forecast period.
As a preventative approach, significant progress is being achieved in the treatment of recurrent migraines. It has led to new approaches to migraine management, empowering clinicians to remain vigilant and continue scientific clinical research while also remembering that the only way to improve chronic migraine detection is to develop a common, shared clinical and scientific management strategy. This contrast between phenotypic and biological markers provides light on previously ignored areas of clinical governance. The clinicians must ensure that emerging and breakthrough therapy alternatives, such as OBT-A and anti-CGRP monoclonal antibodies, are adequately employed in a wider preventative culture to significantly lessen the personal, societal, and economic costs of this dreadful disease.
Increased R&D investment in migraine therapy has resulted in pipeline products, which will result in manufacturers introducing new products to the market, expanding demand, and technological advancements in treating acute migraine. Several research initiatives are now underway, which will most likely give manufacturers a competitive advantage in developing new, innovative, and improved migraine treatment medications and more market potential.
Market Ecosystem
The global migraine therapeutics market is analyzed from the following perspectives by drug class, migraine type, route of administration, and region.
Migraine Therapeutics Market by Drug Class
Based on the drug classes, the global migraine therapeutics market is segmented into CGRP-targeted therapies, antidepressants, anticonvulsants, beta blockers, triptans, opioids, NSAIDS, others (ergotamines, isometheptenes, gepants, ditans, etc.)
Over the forecast period, the triptans segment is expected to grow at an adequate CAGR. Triptans are a newer family of medications that raises serotonin levels in the brain, reducing inflammation and constricting blood vessels, thereby terminating a migraine. Triptans constrict brain blood vessels and block pain pathways. These ergotamines target migraines more specifically than prior ergotamines. Triptans include almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan (Imitrex), sumatriptan with naproxen (Treximet), and zolmitriptan (Zomig). A single-tablet combination of sumatriptan and naproxen sodium (Treximet) is more effective in relieving migraine symptoms than medicine alone.
Furthermore, according to a study titled "Comparison of New Pharmacologic Agents with Triptans for Treatment of Migraine" published in JAMA Network in October 2020, ditans and gepants were associated with less efficacy compared to triptans, but gepants were associated with fewer adverse events compared to triptans. As a result of the triptans' better efficacy, demand for them is predicted to grow, increasing the category throughout the projection period.
Migraine Therapeutics Market by Migraine Type
[85675]
Based on the migraine types, the global migraine therapeutics market is segmented into episodic migraine, chronic migraine.
The episodic migraine segment showed significant growth during the forecast period owing to the rising frequency of neurological illnesses, increasing job pressure, heavy alcohol intake, changes in lifestyles, and increasing demand for quality pharmaceuticals. Furthermore, the growing female population, increased patient awareness about migraine prevention and treatment, growing knowledge of migraine and treatment options, and increased R&D investment, which has resulted in a large pipeline of medicines, are major drivers expected to drive segment growth. However, a lack of proper diagnosis and undiagnosed cases, drug side effects, stringent government regulations, and a growing preference for alternative therapies are major restraining segment growth.
Migraine Therapeutics Market by Route of Administration
Based on the route of administration, the global migraine therapeutics market is segmented into oral, parenteral, and others.
It is preferred because of benefits such as non-invasiveness, patient compliance, and ease of medication delivery. Several factors influence oral drug absorption, including drug solubility, mucosal permeability, and gastrointestinal tract stability. Absorption of medications taken orally may begin in the mouth and stomach. Most medications, however, are absorbed through the small intestine. The medicine goes past the intestinal wall and into the liver before being delivered to its target place through circulation. Many drugs are chemically altered (metabolized) by the intestinal wall and liver, reducing the amount of drug reaching the bloodstream. As a result, these medications are frequently given in lower dosages when administered intravenously to provide the same effect. However, some drugs taken orally irritate the digestive tract. Aspirin, and most other nonsteroidal anti-inflammatory medicines (NSAIDs), for example, can injure the lining of the stomach and small intestine, potentially causing or exacerbating preexisting ulcers. Other drugs are poorly or inconsistently absorbed in the digestive tract or are destroyed by stomach acid and digestive enzymes.
Migraine Therapeutics Market by Region
Based on the regions, the global migraine therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America occupies the largest portion of the global migraine therapeutics market share. The region's dominance is due to the high frequency of migraine, the rising use of innovative therapies, and the big target population in the United States. According to the article "What is Migraine?" published in the JAMA Network in January 2022, 17.1% of women and 5.6% of men in the United States reported experiencing migraine symptoms. As a result of this high incidence, the migraine therapeutics market growth is expected to continue in the United States.
Furthermore, various strategic activities by key market participants, such as product launch and approval, as well as mergers and acquisitions, will drive market growth. For instance, in February 2020, the United States Food and Drug Administration (FDA) approved Lundbeck's VYEPTI (eptinezumab-jjmr) for the prevention of migraine in adults. Likewise, Biohaven Pharmaceutical Holding Company Ltd. received the US Food and Drug Administration (FDA) approval for NURTEC ODT (rimegepant 75 mg) for migraine prevention in May 2021.
The growing focus of suppliers on emerging regions such as Asia Pacific and Latin America is projected to boost market growth. Asia Pacific is predicted to grow greatly in the future due to rising demand for better healthcare facilities and developments in healthcare infrastructure. Because the developed markets are relatively saturated, this area offers excellent possibilities for venture capitalists and investors. The migraine therapeutics market outlook in Asia Pacific is predicted to show gradual growth through the forecast period. This is due to a rise in the number of hospitals and clinics and government efforts to strengthen healthcare infrastructure. Asia Pacific is also the world's largest exporter of pharmaceutical products, emphasizing the need to ensure high-quality drugs for export and giving opportunities for market participants.
Migraine Therapeutics Market Competitive Landscape
Some of the prominent market players in the global migraine therapeutics market include,
Migraine Therapeutics Market Strategic Developments
Migraine is a neurological disorder that produces throbbing, pulsating headaches, nausea, and sensitivity to light, sound, and motion. It can last at least four hours but might extend for days for some people.
North America region is dominating the global migraine therapeutics market.
The oral route of administration led the global migraine therapeutics market.
The revenue CAGR of migraine therapeutics market during the forecast period will be 9.3%.
Some prominent players in the global migraine therapeutics market include Eli Lilly and Company, Allergan, Inc., Biohaven Pharmaceutical Holding Company Ltd.
*Insights on financial performance are subject to the availability of information in the public domain